闫伊森
Lv4
510 积分
2021-10-22 加入
-
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
5天前
已完结
-
SMARCA4: Current status and future perspectives in non-small-cell lung cancer
12天前
已完结
-
Current Management of Stage IIIA (N2) Non-Small-Cell Lung Cancer: Role of Perioperative Immunotherapy, and Tyrosine Kinase Inhibitors
15天前
已完结
-
Unveiling the Untapped Potential of Antibody Drug Conjugates in Precision Oncology
17天前
已完结
-
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
28天前
已完结
-
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
28天前
已完结
-
D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results
30天前
已完结
-
The IASLC Proposed Grading System Accurately Predicts Prognosis and Mediastinal Nodal Metastasis in Patients With Clinical Stage I Lung Adenocarcinoma
30天前
已完结
-
Prognostic Factors for Survival of Stage IB Non-small Cell Lung Cancer Patients: A 10-Year Follow-Up Retrospective Study
1个月前
已完结
-
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
1个月前
已完结